ARTV
ARTV
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
11
$109.18M
Insider Sales
21
$2.74M
Total Volume
$111.92M
32 transactions
Net Activity
+$106.44M
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Strong buying bias: purchases represent 98% of total transaction value.
- •Minor cluster buying: 2 unique insiders purchased shares.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Ra Capital Management, L.P.
Dir, 10%
$92.68M total
Gc Corp.
10%
$16.50M total
Aslan Fred
CEO
$2.04M total
Horan Christopher
Chief Tech Operations Officer
$249K total
Bush Jennifer
COO, CLO, Compliance Officer
$230K total
Quick Actions
ARTV has an insider buy conviction of 98%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at ARTV (ARTV) engaged in a total of 32 transactions reported via SEC Form 4 filings. Among these, 11 were open-market purchases and 21 were sales. The total volume of insider trading reached $111.92M.
The net insider activity for ARTV shows a net buying bias of $106.44M. This activity represents a 98% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Ra Capital Management, L.P. (Dir, 10%), who traded 6.51M shares valued at $75.00M on May 11, 2026.
Artiva Biotherapeutics (ARTV) Stock Forum and Discussion
Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months
ARTV Stock Price and Chart — NASDAQ:ARTV
ARTV - Artiva Biotherapeutics Inc Stock Price and Quote
Should I buy Artiva Biotherapeutics, Inc. (ARTV)
Artiva slumps after discontinuing lead asset
FAQs About ARTV Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ARTV.